May 23, 2017 05:25 PM EDTUpdated May 24, 08:52 AM
Pharma

Pi­o­neer­ing Mer­ck makes an­oth­er break­through with PD-1 star Keytru­da, grab­bing first OK for a can­cer bio­mark­er

John Carroll

Editor & Founder

Mer­ck con­tin­ues to be the trend­set­ter to watch in im­muno-on­col­o­gy. On Tues­day the phar­ma gi­ant nabbed a unique first in the field, grab­bing an FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times